The Role of Tissue Factor Pathway Inhibitor (TFPI) in the Pathogenesis of Lymphatic Malformations

组织因子途径抑制剂 (TFPI) 在淋巴管畸形发病机制中的作用

• 批准号: nhmrc : 1039096
• 负责人: Dr Jenny Than
• 金额: $ 5.81万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Postgraduate Scholarships
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/role-tissue-factor-lymphatic-malformations/111247
• 关键词: Role; Tissue; Factor; Pathway; Inhibitor

Lymphatic malformations or cystic hygomas are growths of abnormal blood vessels called 'lymphatic vessels'. They are present at birth, commonly affect the head and neck, and can cause lifelong problems due to growth in size and frequent infections. Surgical treatment does not offer a cure, and problems often persist lifelong. The finding that blood clots are continuously forming and breaking down in these growths may provide a clue to relieving symptoms and understanding the cause of this condition.

淋巴管畸形或囊性水瘤是称为“淋巴管”的异常血管的生长。它们在出生时就存在，通常会影响头部和颈部，并且由于尺寸的增长和频繁的感染可能导致终身问题。手术治疗不能治愈，问题往往会持续终生。血栓在这些生长中不断形成和分解的发现可能为缓解症状和了解这种情况的原因提供线索。